Parabilis Medicines, Inc. (PBLS) - What Are Analysts Saying About This Stock?

Key Points

• Analysts hold a “Moderate Buy” consensus on Parabilis Medicines, with four buy ratings, one strong buy, one hold, and one sell. The average 12-month price target is $41.67, well above the stock’s recent $25.89 price.
• Institutional interest has increased, with ARCH Venture Management, venBio Partners, Alphabet, Regeneron Pharmaceuticals, and Jupiter Topco collectively establishing or purchasing sizable positions during the second quarter.
• PBLS faces significant financial challenges: its latest quarterly loss of $2.32 per share was far worse than the expected $0.16 loss, revenue was just $0.15 million, and shares have fallen 3.6% while trading near their 12-month low.

Parabilis Medicines, Inc. (NASDAQ:PBLS - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $41.67.

Several brokerages have issued reports on PBLS. Wall Street Zen raised Parabilis Medicines to a "hold" rating in a report on Saturday, June 20th. Guggenheim initiated coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They issued a "buy" rating and a $40.00 target price on the stock. Evercore began coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They set an "outperform" rating on the stock. Weiss Ratings cut shares of Parabilis Medicines from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday, October 2nd. Finally, Lifesci Capital raised Parabilis Medicines to a "strong-buy" rating in a report on Monday, July 6th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. ARCH Venture Management LLC purchased a new position in shares of Parabilis Medicines in the second quarter valued at $175,517,789. venBio Partners LLC acquired a new position in shares of Parabilis Medicines during the 2nd quarter worth $144,149,497. Alphabet Inc. acquired a new position in shares of Parabilis Medicines during the 2nd quarter worth $134,647,000. Regeneron Pharmaceuticals Inc. acquired a new position in shares of Parabilis Medicines during the 2nd quarter worth $114,042,000. Finally, Jupiter Topco LLC purchased a new stake in shares of Parabilis Medicines in the 2nd quarter worth about $62,710,000.

Parabilis Medicines Trading Down 3.6%

Shares of PBLS stock opened at $25.89 on Thursday. The stock's fifty day moving average price is $35.65. The firm has a market capitalization of $3.20 billion and a P/E ratio of -12.15. Parabilis Medicines has a 12 month low of $24.51 and a 12 month high of $42.49.

Parabilis Medicines (NASDAQ:PBLS - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The firm had revenue of $0.15 million during the quarter. As a group, equities analysts expect that Parabilis Medicines will post -3.09 earnings per share for the current fiscal year.

About Parabilis Medicines

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.